Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03827291
Other study ID # PRO00091425
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 31, 2019
Est. completion date December 9, 2022

Study information

Verified date December 2022
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if using a different type of injection of local anesthestic (pain medicine) in between the muscle layers of the abdominal wall (called a quadratus lumborum block) will improve pain control and be easier to manage after surgery than the current standard of care epidural (spinal injection) pain relief for patients undergoing laparoscopy colectomy.


Description:

Participants in this study will receive exparel via an abdominal muscle nerve block procedure immediately prior to their operation. Participants will be in this study for 96 hours following surgery, which is typically 3 days. During participation, the study staff will review participant's electronic health records for pain scores and pain medication needs. Participants that receive the quadratus lumborum block, may experience improved pain control and/or reduced side effects compared to the epidural pain relief option, but it is not known yet whether this will be the case. The most common risk is being sore in the flank where the block was placed. Other risks of the block rarely occur (less than .5-1%), these can include infection, allergy to the local anesthetic, bleeding, damage to the nerve, seizures, abnormal heart rhythms, and cardiac arrest.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date December 9, 2022
Est. primary completion date December 2, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Patients scheduled for elective, laparoscopic colonic resection by one of three surgeons: Drs. Thacker, Mantyh or Migaly. These surgeons perform this procedure in the same manner - Age 18-85 years - American Society of Anesthesiologists (ASA) Physical Class I-III - BMI 18-35 kg/m^2 Exclusion Criteria: - Inability to consent - Inability to speak English - Pregnancy - Emergency surgery - Contraindications to regional blockade: coagulopathy or bleeding diathesis, local infection, allergy to local anesthetics - Allergies/intolerances/contraindications to any of the multimodal agents (acetaminophen, gabapentin, ketorolac) - Daily opioid equivalent use of 30 mg of morphine or greater at time of consent - History of drug or alcohol abuse - Rheumatoid arthritis - Uncontrolled anxiety, schizophrenia or other psychiatric disorder that, in the opinion of the investigator, may interfere with the study assessments of compliance

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Exparel
Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
Other:
Thoracic epidural analgesia
Historical cohort that received thoracic epidural analgesia

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Duke University Pacira Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other 11-point Numeric Rating Scale (NRS-11) Two measures will be taken with each assessment, one at rest and one with coughing. (11-point scale: 10=worst pain imaginable, 0= no pain) 30 minutes after arrival to Post-Anesthesia Care Unit (PACU), and at 8 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours and 168 hours post Exparel administration
Other Block success Presence of demonstrable sensory block over 4 points on the abdomen (one in each of the 4 quadrants), as tested by response to pinprick. Subjects will be asked to report whether the stimulus feels "sharp" or "dull", indicating block failure and success respectively. 30 minutes after arrival to PACU, 8 hours, 24 hours, 36 hours, 48 hours and 72 hours post Exparel administration
Other Adverse Events Subjects will be evaluated for potential adverse events related to the block including evidence of hematoma, infection, unexpected sensory or motor deficit, local anesthetic systemic toxicity, as well as transient weakness of the hip flexor muscles (a known possible side-effect of QL block). From administration of Exparel through 168 hours post Exparel administration
Other Satisfaction with postoperative pain control Overall subject satisfaction with pain control will be recorded on postoperative day 0 and 1 (11-point scale: 10=highly satisfied, 0=completely unsatisfied) From administration of Exparel through 48 hours post Exparel administration
Other Hospital length of stay Measured both by raw length of stay and by time to achieving "discharge readiness", defined by the presence of 3 criteria: a pain score of 3 or less with ambulation, no opioids required in the preceding 6 hours, and the ability to perform self-care (go to the toilet, dress, and shower). From administration of Exparel through hospital discharge
Other Incidence of opioid-related adverse events Incidence of nausea, vomiting, ileus, constipation, orthostasis, pruritis, urinary retention, respiratory depression From administration of Exparel through 168 hours post Exparel administration
Other Time to first mobilization Time to first mobilization From time of arrival in PACU through first mobilization
Other Cost Hospital costs including pharmacy-related costs, costs due to opioid-related adverse events, the cost associated with nursing interventions and drugs to treat opioid-related adverse events, and overall hospital admission costs will be calculated. From time of arrival in PACU through 96 hours post Exparel administration
Other Sleep Quality Two measures will be taken for sleep quality assessment. How much did pain interfere with falling asleep ( 0= no interference, 10= completely interferes). How much did pain interfere with staying asleep (0= no interference, 10= completely interferes). Measures will be taken once daily from POD 1 to POD 7 (approximately 168hrs. after surgery). From administration of Exparel through 168 hours post Exparel administration
Primary Cumulative opioid consumption over 48 hours Opioid consumption from administration of Exparel to 48 hours post-administration Opioid consumption from administration of Exparel to 48 hours post-administration
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT03234543 - Remote Ischemic Conditioning in Abdominal Surgery N/A
Recruiting NCT01719796 - Effect of TAP Block on Ventilatory Function Following Abdominal Surgery Phase 2
Completed NCT02596269 - Nefopam/Fentanyl Postoperative Intravenous Patient-Controlled-Analgesia Phase 2/Phase 3
Completed NCT01723280 - Supplemental Oxygen - Effect on Occurrence of Subsequent Cancer After Abdominal Surgery (Follow-up of the PROXI Trial) N/A
Completed NCT00364741 - Supplemental Oxygen and Complications After Abdominal Surgery (The PROXI-trial) Phase 4
Terminated NCT00514566 - PDS vs Polyamide for Midline Abdominal Closure N/A
Recruiting NCT06089551 - Early vs Postponed Parenteral Nutrition After Emergency Abdominal Surgery Phase 4
Withdrawn NCT03966768 - DuraMesh Laparotomy Study N/A
Recruiting NCT04985695 - Influence of Analgesic Technique on Post Operative Rehabilitation After Median Laparotomy N/A
Recruiting NCT03739944 - Different Surgical Approaches in Patients of Early-stage Cervical Cancer Phase 3
Terminated NCT01890408 - Continuous Preperitoneal Infusion of Ropivacaine After Open Liver Resection: Effect on Post-operative Recovery and Morbidity. Phase 2
Recruiting NCT00544583 - Continuous Versus Interrupted Abdominal Wall Closure After Emergency Midline Laparotomy Phase 2/Phase 3
Recruiting NCT04256798 - Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery Phase 3
Recruiting NCT03738969 - Longitudinal Study of Different Surgical Approaches in Chinese Patients of Uterine Cervical Cancer
Completed NCT03989570 - Transversus Abdominis Plane Block Versus Erector Spinae Plane Block N/A
Not yet recruiting NCT04266535 - TCI vs Manually Controlled Infusion of Propofol
Completed NCT04065607 - Indications and Outcome of Laparostomy
Completed NCT01040013 - Gut Oxygenation and Laparoscopy Phase 2
Completed NCT00637936 - Respiratory Effects of Perioperative Oxygen During General Anaesthesia Phase 4
Recruiting NCT03963882 - NAC Followed by RH for the Treatment of LACC Phase 2